Publication | Closed Access

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Gastrointestinal OncologyMedicineGastroenterologyPhase Ii StudyPathologyHer2-positive Advanced GastricCancer TreatmentOncologyRadiation OncologyGastroesophageal Junction Cancer